These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 11753237)

  • 1. [Medical treatment of digestive neuroendocrine tumours].
    Panzuto F; Nasoni S; Delle Fave G
    Minerva Endocrinol; 2001 Sep; 26(3):145-8. PubMed ID: 11753237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutic strategies for neuroendocrine tumours--can eminence replace evidence?
    Zedenius J
    Acta Oncol; 2008; 47(1):3-4. PubMed ID: 17891671
    [No Abstract]   [Full Text] [Related]  

  • 3. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
    Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L
    Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials].
    Igaz P
    Orv Hetil; 2014 Nov; 155(48):1908-12. PubMed ID: 25417137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
    Banzo J; Abós MD; Prats E; García F; Razola P
    Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
    Oberg K
    Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic therapy for neuroendocrine tumours of gastroenteropancreatic origin.
    Basu B; Sirohi B; Corrie P
    Endocr Relat Cancer; 2010 Mar; 17(1):R75-90. PubMed ID: 20008097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs.
    Imam H; Eriksson B; Lukinius A; Janson ET; Lindgren PG; Wilander E; Oberg K
    Acta Oncol; 1997; 36(6):607-14. PubMed ID: 9408151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.
    Oberg K; Kvols L; Caplin M; Delle Fave G; de Herder W; Rindi G; Ruszniewski P; Woltering EA; Wiedenmann B
    Ann Oncol; 2004 Jun; 15(6):966-73. PubMed ID: 15151956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors.
    Janson ET; Kälkner KM; Eriksson B; Westlin JE; Oberg K
    Nucl Med Biol; 1999 Nov; 26(8):877-82. PubMed ID: 10708300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Somatostatin analogs in the clinical management of pituitary neoplasms].
    Colao A; Dorato M; Pulcrano M; Rossi FW; Auriemma RS; Lombardi G; Lastoria S
    Minerva Endocrinol; 2001 Sep; 26(3):181-91. PubMed ID: 11753242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
    Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
    Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of (111)In labeled somatostatin analogs for targeted therapy of somatostatin receptor positive tumors.
    Bernhardt P; Ahlman H; Nilsson O; Benjegård SA; Forssell-Aronsson E
    Cancer Biother Radiopharm; 2003 Apr; 18(2):249-52. PubMed ID: 12804051
    [No Abstract]   [Full Text] [Related]  

  • 15. Liver metastases of digestive endocrine tumours: natural history and response to medical treatment.
    Skinazi F; Zins M; Menu Y; Bernades P; Ruszniewski P
    Eur J Gastroenterol Hepatol; 1996 Jul; 8(7):673-8. PubMed ID: 8853257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
    Boussaha T; Rougier P; Taieb J; Lepere C
    Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
    Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
    J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.
    Slooter GD; Mearadji A; Breeman WA; Marquet RL; de Jong M; Krenning EP; van Eijck CH
    Br J Surg; 2001 Jan; 88(1):31-40. PubMed ID: 11136306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Biotherapy of neuroendocrine tumours of the gastrointestinal tract and pancreas].
    Hansen CP; Knigge U
    Ugeskr Laeger; 2008 Jun; 170(24):2145-8. PubMed ID: 18565299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic reliability of somatostatin receptor scintigraphy during continuous treatment with different somatostatin analogs.
    Dörr U; Wurm K; Höring E; Guzman G; Räth U; Bihl H
    Horm Metab Res Suppl; 1993; 27():36-43. PubMed ID: 8330870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.